Neutrolis is Developing Treatments for COVID-19 Patients

COVID-19 causes a severe immune response and several unusual side effects.

Severe COVID-19 is caused by the body’s overreacting immune response and not the activity of the virus itself. Specifically, COVID-19 patients can develop Acute Respiratory Distress Syndrome (ARDS), which is respiratory failure characterized by rapid onset of a severe immune response in the lungs, and is the primary cause of death from COVID-19. In addition, COVID-19 has been known to cause a series of unusual conditions, such as stroke, heart attack, kidney failure, and multisystem inflammatory syndrome in children.

NETs role in COVID-19 disease progression.

Neutrophil Extracellular Traps (NETs) are a key mediator of ARDS and have been observed in the lungs of COVID-19 patients with ARDS. Once released in the pulmonary system, NETs can cause organ damage by physical occlusion of the alveolar architecture and function as well as by activating an immune response that recruits a storm of other inflammatory cells and antibodies. In addition, NETs have been associated with the formation of blood clots (thrombosis), kidney damage and systemic inflammation among other sequela. See references below.

NTR-441 for treatment of critically ill COVID-19 patients

In response to this urgent global health need, Neutrolis is developing NTR-441 to treat the overreacting immune response and thrombosis in patients with severe COVID-19. Please contact us if you would like to learn more about how our program can help COVID-19 patients.

©2020, Neutrolis. All Rights Reserved.

Site Credit

Neutrophil Scientific Illustrations: Gary Carlson